The purpose of this study is to determine whether iloperidone is effective in the treatment of Schizophrenia.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Enrollment
260
Iloperidone is being development as a treatment of schizophrenia. This trial will verify the safety and efficacy of iloperidone in patients with schizophrenia.
Risperidone is used for the treatment of schizophrenia.Risperidone is unique among most other atypicals in that it has high affinity for the D2 receptor whereas most other atypicals have 'loose binding' of the D2 receptor. It has actions at several 5-HT (serotonin) receptor subtypes.
Sixth Hospital of Peking University
Beijing, Beijing Municipality, China
Positive and Negative Symptom Scale(PANSS)-Total Score
Time frame: 6 weeks
Effective percentage(PANSS score reduce rate≥50%)
Time frame: 6 weeks
Change in scores from baseline to end point assessment on the PANSS Positive subscale (PANSS-P)
Time frame: 6 weeks
Change in scores from baseline to end point assessment on the PANSS Negative subscale (PANSS-N)
Time frame: 6 weeks
Change in scores from baseline to end point assessment on the PANSS General Psychopathology subscale(PANSS-GP)
Time frame: 6 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.